Jay Stout
Chief Tech/Sci/R&D Officer at IMMUNOVANT, INC.
Net worth: 4 M $ as of 30/05/2024
Jay Stout active positions
| Companies | Position | Start | End |
|---|---|---|---|
| IMMUNOVANT, INC. | Chief Tech/Sci/R&D Officer | 31/03/2023 | - |
Career history of Jay Stout
Former positions of Jay Stout
| Companies | Position | Start | End |
|---|---|---|---|
| IMMUNOMEDICS, INC. | Chief Tech/Sci/R&D Officer | - | - |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Chief Tech/Sci/R&D Officer | 24/04/2017 | - |
Training of Jay Stout
| The University of Nebraska-Lincoln | Doctorate Degree |
| University of Iowa | Graduate Degree |
Statistics
International
| United States | 6 |
Operational
| Chief Tech/Sci/R&D Officer | 3 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| IMMUNOVANT, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
- Stock Market
- Insiders
- Jay Stout
- Experience